New Zealand markets closed

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
183.52-3.57 (-1.91%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 546.90B
Enterprise value 341.09B
Trailing P/E 23.85
Forward P/E 114.01
PEG ratio (5-yr expected) 10.29
Price/sales (ttm)7.09
Price/book (mrq)5.10
Enterprise value/revenue 36.15
Enterprise value/EBITDA 715.87

Trading information

Stock price history

Beta (5Y monthly) 0.66
52-week change 3-11.41%
S&P500 52-week change 333.64%
52-week high 3242.99
52-week low 3176.36
50-day moving average 3184.07
200-day moving average 3199.42

Share statistics

Avg vol (3-month) 31.71M
Avg vol (10-day) 31.83M
Shares outstanding 5259.43M
Implied shares outstanding 6N/A
Float 8258.85M
% held by insiders 10.13%
% held by institutions 191.95%
Shares short (29 Sep 2021) 45.07M
Short ratio (29 Sep 2021) 43.72
Short % of float (29 Sep 2021) 41.96%
Short % of shares outstanding (29 Sep 2021) 41.95%
Shares short (prior month 30 Aug 2021) 44.83M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 22:1
Last split date 323 Aug 2000

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021

Profitability

Profit margin 29.80%
Operating margin (ttm)33.93%

Management effectiveness

Return on assets (ttm)12.63%
Return on equity (ttm)23.83%

Income statement

Revenue (ttm)6.68B
Revenue per share (ttm)25.76
Quarterly revenue growth (yoy)17.60%
Gross profit (ttm)3.64B
EBITDA 2.38B
Net income avi to common (ttm)1.99B
Diluted EPS (ttm)7.59
Quarterly earnings growth (yoy)-92.00%

Balance sheet

Total cash (mrq)6.71B
Total cash per share (mrq)25.86
Total debt (mrq)893.85M
Total debt/equity (mrq)9.72
Current ratio (mrq)4.61
Book value per share (mrq)35.49

Cash flow statement

Operating cash flow (ttm)2.12B
Levered free cash flow (ttm)1.1B